HELP PEOPLE WITH CANCER
LIVE LONGER AND BETTER
1
MORE3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.
Candidate Molecule
Target/
Mechanism
Rights
Preclinical
IND
Phase I
Phase II
Phase Ⅲ
NDA
Partner
Candidate
Molecule
Target/
Mechanism
Rights
Preclinical
IND
Phase I
Phase Ⅱ
Phase Ⅲ
NDA
Partner
MSI-H/dMMR advanced cancer (mono, 2L+)
Advanced BTC (combo with chemo vs. chemo, 1L)
NSCLC (Adjuvant/Neo-adjuvant therapy, 1L)
G/GEJ advanced cancer (combo with chemo, 1L)
TMB-H advanced cancer (mono, 2L+)
EC (mono and combo with lenvatinib, 2L+)
HCC, CRC, NSCLC (combo with BD0801)
Microsatellite stable CRC (combo with cetuximab+/- Fruquintinib, standard treatment failure)
dMMR advanced solid tumors (mono, 2L+)
Multiple indications
As a young biotechnology company, our goal is to achieve several milestones and make profitable innovation. We are steadfast in strengthening our internal discovery capability and conducting pivotal clinical trials to address unmet medical needs to provide more treatment options for cancer patients.
we are confident that we are well-positioned to achieve our vision of transforming cancer from a terminal illness into a manageable chronic disease. We have a robust pipeline of differentiated cancer therapies that address unmet medical needs in the future and offer significant valuation to patients, physicians, and payers. We have a talented and passionate team of scientists, clinicians and professionals who are committed to delivering on our promise of bringing hope and healing to millions of cancer patients around the world
-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.
News
(Hong Kong, December 15 , 2022) A biopharmaceutical company in China for the development and commercialization of next-generation tumor immunotherapy drugs - 3D Medicines Inc. (“ 3D Medicines” or the “Company”, Stock Code: 1244.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange”) today.
2022-12
15
News
2024-05
13
News
Beijing, China October 8, 2022- 3D Medicines Inc. announced today that the subject has been dosed in the Phase I clinical trial for 3D189 (also known as galinpepimut-S, or GPS), which is the first clinical trial in China for this product to assess the safety and immunogenicity of 3D189 in patients with hematological malignancies. The first dosing of the first participant was completed. 3D Medicines holds the exclusive license from SELLAS to develop, manufacture and commercialize 3D189 in China, Hong Kong, Macau and Taiwan region for all therapeutic and other diagnostic uses.
2022-10
10